Australia’s CSL has announced plans to expand its US presence over the next five years, resulting in approximately $1.5 billion in capital investments.
Swiss generics and biosimilars company Sandoz has announced the launch of Tyruko (natalizumab-sztn) in the USA.
A major British initiative is set to repurpose used nuclear materials, converting them into a consistent supply for innovative cancer treatments. The £9.9 million ($13 million) from the Innovate UK ...
Spanish plasma-based medicines producer Grifols today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for THROMBATE III, the company’s antithrombin III ...
South Korean clinical-stage biotech ABL Bio has entered license, research and collaboration agreement with US pharma major Eli Lilly for the development of therapeutics by utilizing ABL Bio’s Grabody ...
South Korean biosimilars developer Celltrion today announced that the European Commission (EC) has granted marketing authorization for Remsima IV (intravenous) liquid formulation, the world’s first ...
New government funding will help make the boldest ideas in UK life sciences a reality – from putting robots to work in factories making medicines, to turning spent nuclear fuel into the next ...
Canadian firm Zymeworks, a biotech managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, has announced a new strategy.
Roche today announced positive Phase III results from the lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrine treatment for people with oestrogen receptor ...
The US Food and Drug Administration today announced it has approved Danish biotech firm Genmab’s Epkinly (epcoritamab-bysp) with lenalidomide and rituximab for relapsed or refractory follicular ...
Shares of US clinical-stage biopharmaceutical company Nuvalent jumped more than 15% to $111.22 by midday yesterday, after it announced positive top-line pivotal data for neladalkib.
A clinical‑stage biotech company headquartered in Antwerp, Belgium, developing organ‑restricted therapies for fibrotic disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback